| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/09/2009 | US20090092622 Molecules, compositions, methods and kits for applications associated with flaviviruses |
| 04/09/2009 | US20090092621 Antibodies for preventing and treating attaching and effacing escherichia coli (aeec) associated diseases |
| 04/09/2009 | US20090092620 Flu virus hemagglutinin specific monoclonal antibodies |
| 04/09/2009 | US20090092619 Methods and compositions for malaria prophylaxis |
| 04/09/2009 | US20090092618 Peptide-based immunization therapy for treatment of atherosclerosis |
| 04/09/2009 | US20090092617 Erbb Receptor-Derived Peptide Fragments |
| 04/09/2009 | US20090092616 ZNF206: A Novel Regulator of Embryonic Stem Cell Self-renewal and Pluripotency |
| 04/09/2009 | US20090092615 biodrugs select from an oligopeptide, or polypeptide; anticarcinogenic agent for treating lung cancer cell, adenocarcinoma cell; combination therapy using standard anti-cancer protocols in conjunction with Notch proteins |
| 04/09/2009 | US20090092614 Anti-IGF-1R Antibodies and Uses Thereof |
| 04/09/2009 | US20090092613 Novel TNF receptor death domain ligand proteins and inhibitors of ligand binding |
| 04/09/2009 | US20090092612 Anti-platelet membrane glycoprotein vi monoclonal antibody |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092610 FcGammaRIIB Specific Antibodies and Methods of Use Thereof |
| 04/09/2009 | US20090092609 Monoclonal antibodies to respiratory syncytial virus and uses therefor |
| 04/09/2009 | US20090092608 Human Tumor Necrosis Factor Receptor-Like 2 |
| 04/09/2009 | US20090092607 Fc-erythropoietin fusion protein with improved pharmacokinetics |
| 04/09/2009 | US20090092606 Antibacterial treatments |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092604 Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity |
| 04/09/2009 | US20090092603 Early diagnosis and treatment of drug resistance in muc1-positive cancer |
| 04/09/2009 | US20090092602 Use of anti-tissue factor antibodies for treating thromboses |
| 04/09/2009 | US20090092601 HUMANIZED ANTI-LT-beta-R ANTIBODIES |
| 04/09/2009 | US20090092600 Methods and compositions relating to the regulation of muc1 by hsf1 and stat3 |
| 04/09/2009 | US20090092599 Optimized Fc variants and methods for their generation |
| 04/09/2009 | US20090092598 administering anti-CEA (carcinogenicembryonic antigen) monoclonal antibody (MAb) or fragment and a drug selected from vincristine, doxorubicin, dacarbazine (DTIC), cyclophosphamide, CPT-11, oxaliplatin, gemcitabine and 5-fluorouracil/leucovorin |
| 04/09/2009 | US20090092597 Mammalian cell surface antigens; related reagents |
| 04/09/2009 | US20090092596 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| 04/09/2009 | US20090092595 Suppression of sPLA2-integrin binding for treating an inflammatory condition |
| 04/09/2009 | US20090092594 Mammalian genes involved in viral infection and tumor suppression |
| 04/09/2009 | US20090092593 Therapeutic drug for heart disease and virus disease |
| 04/09/2009 | US20090092592 Methionyl tRNA Synthetase Polynucleotides |
| 04/09/2009 | US20090092581 Interferons of rhesus and cynomolgus origin and uses thereof |
| 04/09/2009 | US20090092580 Dialkyl ether delivery agents |
| 04/09/2009 | US20090092579 Novel method for down-regulation of amyloid |
| 04/09/2009 | US20090092578 Methods of selecting and producing modified toxins, conjugates containing modified toxins, and uses thereof |
| 04/09/2009 | US20090092557 Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use |
| 04/09/2009 | US20090092551 Increasing lifespan by modulation of pha-4 |
| 04/09/2009 | US20090092546 Carrier molecules |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092544 Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody |
| 04/09/2009 | US20090092543 Methods of treating and preventing inflammatory bowel disease involving il-13 and nkt cells |
| 04/09/2009 | DE19543553B4 VP-Antigene des JC-Virus VP-antigens of the JC virus |
| 04/09/2009 | CA2734139A1 Antibody therapy for use in the digestive tract |
| 04/09/2009 | CA2701846A1 Extracellular targets for alzheimer's disease |
| 04/09/2009 | CA2701719A1 Dry powders of cellular material |
| 04/09/2009 | CA2701694A1 Antigen-binding proteins having specificity for human hepcidin |
| 04/09/2009 | CA2701172A1 Methods of treating neurological autoimmune disorders with cyclophosphamide |
| 04/09/2009 | CA2701155A1 Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient |
| 04/09/2009 | CA2700860A1 Human antibodies that bind mesothelin, and uses thereof |
| 04/09/2009 | CA2700828A1 Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| 04/09/2009 | CA2700758A1 Immunoglobulins |
| 04/09/2009 | CA2699601A1 Nlrr-1 antagonists and uses thereof |
| 04/09/2009 | CA2697992A1 B7 family member zb7h6 and related compositions and methods |
| 04/09/2009 | CA2696417A1 Therapeutic antibody purification method and method of use |
| 04/08/2009 | EP2045329A1 Flagellin mutant vaccine |
| 04/08/2009 | EP2045328A1 Peptide and nucleotide sequences of anisakis spp., antibodies that recognise said sequences and uses of same |
| 04/08/2009 | EP2045322A1 Double-muscling in mammals |
| 04/08/2009 | EP2045268A1 Mhc class I and II peptide antigens derived from tumour antigen 5t4 |
| 04/08/2009 | EP2045267A2 Humanized antibodies that recognize beta amyloid peptide |
| 04/08/2009 | EP2045261A1 Chlamydia pneumoniae antigenic polypeptides |
| 04/08/2009 | EP2044956A1 Hematopoietic stem cell proliferation promoter |
| 04/08/2009 | EP2044955A2 Methods for detecting and inhibiting angiogenesis |
| 04/08/2009 | EP2044954A1 Treatment of fungal infections |
| 04/08/2009 | EP2044953A1 Viral antigens |
| 04/08/2009 | EP2044950A2 Attenuated VIF DNA immunization cassettes for genetic vaccines |
| 04/08/2009 | EP2044948A1 Methods and compositions concerning poxviruses and cancer |
| 04/08/2009 | EP2044947A1 Compositions and methods |
| 04/08/2009 | EP2044198A2 Chimeric influenza virus-like particles |
| 04/08/2009 | EP2044125A1 Compositions and methods for delivering anti-activated ras antibodies into cells |
| 04/08/2009 | EP2044123A1 Tumor-targeting monoclonal antibodies to fzd10 and uses thereof |
| 04/08/2009 | EP2044122A2 Antagonist antibody against epha2 for the treatment of cancer |
| 04/08/2009 | EP2044119A1 Cancerous disease modifying antibodies |
| 04/08/2009 | EP2044118A2 Il-17 and il-23 antagonists and methods of using the same |
| 04/08/2009 | EP2043690A1 Use of alpha-toxin for treating and preventing staphylococcus infections |
| 04/08/2009 | EP2043687A2 Anti-amyloid antibodies, compositions, methods and uses |
| 04/08/2009 | EP2043686A2 Antagonists of protease activated receptor-1 (par1) |
| 04/08/2009 | EP2043685A1 Prevention of rash in patients undergoing anti-egfr therapy |
| 04/08/2009 | EP2043684A1 A method for the production of hydrolyzed allergen |
| 04/08/2009 | EP2043683A2 Frozen stockpiling of influenza vaccines |
| 04/08/2009 | EP2043682A1 Influenza vaccine |
| 04/08/2009 | EP2043680A1 Method of immunisation against the four serotypes of dengue |
| 04/08/2009 | EP2043679A2 Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| 04/08/2009 | EP2043666A2 Activated myeloid cells for promoting tissue repair and detecting damaged tissue |
| 04/08/2009 | EP1673393B1 Methods, kits, and compositions for the development and use of monoclonal antibodies specific to antigens of low immunogenicity |
| 04/08/2009 | EP1559318B1 Transgenic mammal carrying ganp gene transferred thereinto and utilization thereof |
| 04/08/2009 | EP1539808B1 gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS |
| 04/08/2009 | EP1519749B1 Chemotactic factor inhibitor for inhibiting inflammatory reactions |
| 04/08/2009 | EP1505076B1 Specific antibody fragments for the human carcinoembryonic antigen (cea) |
| 04/08/2009 | EP1501921B1 Improved viral purification methods |
| 04/08/2009 | EP1476468B9 Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity |
| 04/08/2009 | EP1244692B1 Compositions and methods for detecting stress-inducible proteins |
| 04/08/2009 | EP1235589B1 Compositions comprising neisseria meningitidis antigens from serogroups b and c as well as a further antigen |
| 04/08/2009 | EP1096953B1 Use of inactivated immunosuppressive and/or angiogenic immunogenic proteins, preparation method and pharmaceutical or vaccine uses |
| 04/08/2009 | EP1007569B1 Stimulation of an immune response with antibodies labeled with the alpha-galactosyl epitope |
| 04/08/2009 | EP0877758B1 PURIFIED SR-p70 PROTEIN |
| 04/08/2009 | CN101405408A Methods of increasing lymphatic function |
| 04/08/2009 | CN101405386A Tuberculosis vaccine |
| 04/08/2009 | CN101405300A Methods and compositions for antagonism of RAGE |
| 04/08/2009 | CN101405030A Tumor therapy with an antibody for vascular endothelial groeth factor and an antibody for human epithelial growth factor receptor type 2 |
| 04/08/2009 | CN101405029A Treatment of metastatic breast cancer |